Everything below concerns copper(II) complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Dry, protected from light |
| Appearance in solution | Blue | Tone varies with pH and concentration |
| Primary analytical method | LC-MS with ICP-MS | Identity plus copper content |
| pH sensitivity | Higher near neutral and above | Alkaline conditions can degrade it |
| Common supplied form | Freeze-dried solid | Dissolved before use |
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
== Pathophysiology == The human skin consists of two layers: an outermost layer called the epidermis and a layer underneath called the dermis. In individuals with healthy skin, there are protein anchors between these two layers (dermo-epidermal junction) that prevent them from moving independently from one another (shearing). In people born with EB, the two skin layers lack the protein anchors that hold them together, resulting in extremely fragile skin—even minor mechanical friction (like rubbing or pressure) or trauma will separate the layers of the skin and form blisters and painful sores. EB individuals manifest unremitting skin blistering that evolves into chronic wounds, inflammation, and fibrosis. People with EB have compared the sores with third-degree burns. Furthermore, as a complication of the chronic skin damage, people with EB have an increased risk of malignancies (cancers) of the skin. Virtually any organ lined or covered by epithelium may be injured in inherited EB. External eye, esophagus, upper airway, and genitourinary tract are the epithelial surfaced tissues that are at particular risk.
== Signs and symptoms == Individuals with Stickler syndrome experience a range of signs and symptoms. Some people have no signs and symptoms; others have some or all of the features described below. In addition, each feature of this syndrome may vary from subtle to severe. A characteristic feature of Stickler syndrome is a somewhat flattened facial appearance. This is caused by underdeveloped bones in the middle of the face, including the cheekbones and the bridge of the nose. A particular group of physical features, called the Pierre Robin sequence, is common in children with Stickler syndrome. Pierre Robin sequence includes a U-shaped or sometimes V-shaped cleft palate (an opening in the roof of the mouth) with a tongue that is too large for the space formed by the small lower jaw. Children with a cleft palate are also prone to ear infections and occasionally swallowing difficulties. Many people with Stickler syndrome are very nearsighted (described as having high myopia) because of the shape of the eye. People with eye involvement are prone to increased pressure within the eye (ocular hypertension) which could lead to glaucoma and tearing or detachment of the light-sensitive retina of the eye (retinal detachment). Cataract may also present as an ocular complication associated with Stickler's Syndrome. The jelly-like substance within the eye (the vitreous humour) has a distinctive appearance in the types of Stickler syndrome associated with the COL2A1 and COL11A1 genes. As a result, regular appointments to a specialist ophthalmologist are advised.
== Further reading == Inglis, Julia J.; Criado, Gabriel; Medghalchi, Mino; Andrews, Melanie; Sandison, Ann; Feldmann, Marc; Williams, Richard O. (29 October 2007). "Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen". Arthritis Research & Therapy. 9 (5): R113. doi:10.1186/ar2319. ISSN 1478-6354. PMC 2212575. PMID 17967186. Pietrosimone, K. M.; Jin, M.; Poston, B.; Liu, P. (20 October 2015). "Collagen-Induced Arthritis: A model for Murine Autoimmune Arthritis". Bio-Protocol. 5 (20) e1626. doi:10.21769/bioprotoc.1626. ISSN 2331-8325. PMC 4629450. PMID 26539560. Holmdahl, Rikard; Bockermann, Robert; Bäcklund, Johan; Yamada, Hisakata (1 February 2002). "The molecular pathogenesis of collagen-induced arthritis in mice—a model for rheumatoid arthritis". Ageing Research Reviews. 1 (1): 135–147. doi:10.1016/S0047-6374(01)00371-2. ISSN 1568-1637. PMID 12039453. S2CID 28243127.
Sources: en.wikipedia.org
Cuba experienced its lowest-ever temperature of 0 °C (32 °F) on 3 February as measured at a weather station in Matanzas Province. On 4 February, the eastern provinces of Guantánamo, Santiago de Cuba, Holguín and Granma suffered a total blackout, while the western part of the island and Havana suffered serious difficulties with electricity. On 4 March, a shutdown of the Antonio Guiteras Power Plant resulted in power outages for millions of Cubans in the western part of the country. On 16 March, Cuba's power grid collapsed leaving the country without power.
In anatomy, a fistula (pl.: fistulas or fistulae ; from Latin fistula 'tube, pipe') is an abnormal connection (i.e. tube) joining two hollow spaces (technically, two epithelialized surfaces), such as blood vessels, intestines, or other hollow organs to each other, often resulting in an abnormal flow of fluid from one space to the other. An anal fistula connects the anal canal to the perianal skin. An anovaginal or rectovaginal fistula is a hole joining the anus or rectum to the vagina. A colovaginal fistula joins the space in the colon to that in the vagina. A urinary tract fistula is an abnormal opening in the urinary tract or an abnormal connection between the urinary tract and another organ. An abnormal communication (i.e. hole or tube) between the bladder and the uterus is called a vesicouterine fistula, while if it is between the bladder and the vagina it is known as a vesicovaginal fistula, and if between the urethra and the vagina: a urethrovaginal fistula. When occurring between two parts of the intestine, it is known as an enteroenteral fistula, between the small intestine and the skin it is known as an enterocutaneous fistula, and between the colon and the skin as a colocutaneous fistula. A fistula can result from an infection, inflammation, injury or surgery. Many result from complications during childbirth. Sometimes a fistula is deliberately surgically created as part of a treatment, for example in the case of an arteriovenous fistula for hemodialysis.
trend predicted for rigid elastic spheres. Indeed, the Chapman–Enskog analysis shows that the predicted temperature dependence can be tuned by varying the parameters in various molecular models. A simple example is the Sutherland model, which describes rigid elastic spheres with weak mutual attraction. In such a case, the attractive force can be treated perturbatively, which leads to a simple expression for
== Effects of supplementation on exercise == BCAAs have an insulin-like effect on glucose, lowering circulating glucose concentrations. When ingested before exercise, they can be oxidized by skeletal muscle and used as an energy source, reducing the need for the liver to increase glycogenolysis. During anaerobic exercise, pyruvate derived from glucose metabolism is converted into lactic acid. The accumulation of lactic acid can lower pH to as low as 6.4, contributing to metabolic acidosis. Elevated lactic acid levels inhibit glucose metabolism to prevent further acidification. BCAA supplementation has been reported to decrease lactic acid concentrations in muscle, thereby allowing glucose metabolism to continue during exercise. This effect reduces glycogenolysis in the liver and lowers plasma glucose during exercise, although long-term supplementation appears to have little effect on blood glucose outside of exercise. BCAAs also influence central fatigue mechanisms. They reduce circulating free fatty acids (FFA), which compete with tryptophan for binding to albumin. Lower FFA levels increase albumin-bound tryptophan, thereby decreasing free tryptophan entry into the brain. Since free tryptophan is a precursor to serotonin (5-HT), reduced tryptophan uptake lowers serotonin synthesis during exercise, diminishing the sensation of fatigue. In rats, BCAA supplementation reduced brain serotonin by up to 90%, though such reductions can also impair focus, impulse control, and executive function.
Sources: en.wikipedia.org
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
== Company history == BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
Demoxytocin (INN; brand names Sandopart, Odeax, Sandopral; also known as desaminooxytocin, deaminooxytocin, 1-(3-mercaptopropanoic acid)oxytocin, and [Mpa1]OT) is an oxytocic peptide drug that is used to induce labor, promote lactation, and to prevent and treat puerperal (postpartum) mastitis (breast inflammation). Demoxytocin is a synthetic analogue of oxytocin and has similar activities, but is more potent and has a longer half-life in comparison. Unlike oxytocin, which is given via intravenous injection, demoxytocin is administered as a buccal tablet formulation. The drug was first synthesized in 1960 and was introduced into clinical practice in 1971 by Sandoz. It is marketed in several European countries, including Italy, Czech Republic, and Poland. It has the amino acid sequence Mpa-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Mpa = β-mercaptopropionic acid), and is an analogue of oxytocin wherein the leading cysteine is replaced with β-mercaptopropionic acid.
Sources: en.wikipedia.org
Freezer temperatures are common for long-term retention. Light and moisture exposure should be limited. Working portions are best kept cold and used without repeated freeze-thaw cycles.
Sequence assays confirm the amino acids but say nothing about the metal. Copper content links the peptide to the ion that defines the complex. An elemental technique is used for this step.
No. Several copper species and degraded mixtures can also look blue. Confirmation needs both separation data and elemental data.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.